In Vitro Evaluation of Antimicrobial Properties of Some New 1, 3, 4-Oxadiazole Derivatives against Acinetobacter baumannii

Document Type : Original Research

Authors
1 Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran
2 Department of Chemistry, Urmia Branch, Islamic Azad University, Urmia, Iran
Abstract
Aims: The need for new antibacterial drugs is justified because many pathogens are currently resistant to available antibacterial drugs, and this is an alarming threat to the health of future generations. 1, 3, 4‑Oxadiazole has been shown to pose a wide range of antibacterial activity. Some of the marketed drugs also possess this heterocyclic moiety.

Materials & Methods: The new derivatives of 1, 3, 4-oxadiazole were synthesized using a single-stage, high-yield method. Then, to measure the antibacterial activity of prepared derivatives agar well diffusion method was employed, and the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) were determined at a concentration of 1mg/mL with three replications.

Findings: Compounds 4a, 4d, and 4i exhibited a promising antibacterial activity against Acinetobacter baumannii PTCC1855. Among the three compounds mentioned, compound 4i showed the best performance with IZ=22±0.75 m.m , MIC=500µg/mL and MBC=125µg/mL at a concentration of 1mg/mL.

Conclusion: The new 1, 3, 4‑Oxadiazole derivative (4i) was shown to be a promising compound for pharmaceutical applications, by adding other functional groups to its structure, it is possible to increase the destructive power of the compound.

Keywords

Subjects


1- Figueiredo J, Serrano JL, Soares M, Ferreira S, Domingues FC, Almeida P, Silvestre S. 5-Hydrazinylethylidenepyrimidines effective against multidrug-resistant Acinetobacter baumannii: Synthesis and in vitro biological evaluation of antibacterial, radical scavenging and cytotoxic activities. European Journal of Pharmaceutical Sciences. 2019 Sep 1;137:104964.
2- Zhang D, Xia J, Xu Y, Gong M, Zhou Y, Xie L, Fang X. Biological features of biofilm-forming ability of Acinetobacter baumannii strains derived from 121 elderly patients with hospital-acquired pneumonia. Clinical and experimental medicine. 2016 Feb 1;16(1):73-80.
3- Khaled DW, Abdullah BA. Antibiotic Resistant Infection of the Bacterial Group ESKAPE. Sci. J. Med. Res. 2018;2(8):166-71.
4- Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infection and drug resistance. 2018;11:1249.
5- Schweppe DK, Harding C, Chavez JD, Wu X, Ramage E, Singh PK, Manoil C, Bruce JE. Host-microbe protein interactions during bacterial infection. Chemistry & biology. 2015 Nov 19;22(11):1521-30.
6- Kim SW, Oh MH, Jun SH, Jeon H, Kim SI, Kim K, Lee YC, Lee JC. Outer membrane Protein A plays a role in pathogenesis of Acinetobacter nosocomialis. Virulence. 2016 May 18;7(4):413-26.
7- Nho JS, Jun SH, Oh MH, Park TI, Choi CW, Kim SI, Choi CH, Lee JC. Acinetobacter nosocomialis secretes outer membrane vesicles that induce epithelial cell death and host inflammatory responses. Microbial pathogenesis. 2015 Apr 1;81:39-45.
8- Lee S, Al Razqan GS, Kwon DH. Antibacterial activity of epigallocatechin-3-gallate (EGCG) and its synergism with β-lactam antibiotics sensitizing carbapenem-associated multidrug resistant clinical isolates of Acinetobacter baumannii. Phytomedicine. 2017 Jan 15; 24:49-55.
9- Manchanda V, Sanchaita S, Singh NP. Multidrug resistant acinetobacter. Journal of global infectious diseases. 2010 Sep; 2(3):291.
10- Valencia R, Arroyo LA, Conde M, Aldana JM, Torres MJ, Fernández-Cuenca F, Garnacho-Montero J, Cisneros JM, Ortiz C, Pachón J, Aznar J. Nosocomial outbreak of infection with pan–drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infection Control & Hospital Epidemiology. 2009 Mar; 30(3):257-63.
11- Pourhajibagher M, Hashemi FB, Pourakbari B, Aziemzadeh M, Bahador A. Antimicrobial resistance of Acinetobacter baumannii to imipenem in Iran: a systematic review and meta-analysis. The open microbiology journal. 2016; 10:32.
12- Zheng Z, Liu Q, Kim W, Tharmalingam N, Fuchs BB, Mylonakis E. Antimicrobial activity of 1, 3, 4-oxadiazole derivatives against planktonic cells and biofilm of Staphylococcus aureus. Future medicinal chemistry. 2018 Feb; 10(3):283-96.
13- Khalilullah H, Khan S, Nomani MS, Ahmed B. Synthesis, characterization and antimicrobial activity of benzodioxane ring containing 1, 3, 4-oxadiazole derivatives. Arabian Journal of Chemistry. 2016 Nov 1; 9:S1029-35.

14- Gurjar MK, Sonawane SP, Maikap GS, Patil GD, Shinde SB, Shalikrao P, Mehta SS, inventors; Emcure Pharmaceuticals Ltd, assignee. Synthesis of Raltegravir. United States patent US 9,475,799. 2016 Oct 25.
15- Souldozi A. Efficient one-pot three-component reaction for the synthesis of (5-aryl-1, 3, 4-oxadiazol-2-yl)(pyridin-2-yl) methanol derivatives. Journal of Chemical Research. 2015 Apr; 39(3):177-9.
16- Wang L, Cao J, Chen Q, He M. One-pot synthesis of 2, 5-diaryl 1, 3, 4-oxadiazoles via di-tert-butyl peroxide promoted N-acylation of aryl tetrazoles with aldehydes. The Journal of organic chemistry. 2015 May 1; 80(9):4743-8.
17- Wong MY, Krotkus S, Copley G, Li W, Murawski C, Hall D, Hedley GJ, Jaricot M, Cordes DB, Slawin AM, Olivier Y. Deep-blue oxadiazole-containing thermally activated delayed fluorescence emitters for organic light-emitting diodes. ACS applied materials & interfaces. 2018 Sep 7; 10(39):33360-72.

18- Rohand T, Ramli Y, Baruah M, Budka J, Das AM. Synthesis, structure elucidation and antimicrobial properties of new bis-1, 3, 4-oxadiazole derivatives. Pharmaceutical Chemistry Journal. 2019 May 5; 53(2):150-4.

19- Karaburun AÇ, Kaya Çavuşoğlu B, Acar Çevik U, Osmaniye D, Sağlık BN, Levent S, Özkay Y, Atlı Ö, Koparal AS, Kaplancıklı ZA. Synthesis and antifungal potential of some novel benzimidazole-1, 3, 4-oxadiazole compounds. Molecules. 2019 Jan; 24(1):191.
20- Makane VB, Krishna VS, Krishna EV, Shukla M, Mahizhaveni B, Misra S, Chopra S, Sriram D, Azger Dusthackeer VN, Rode HB. Novel 1, 3, 4-oxadiazoles as antitubercular agents with limited activity against drug-resistant tuberculosis. Future medicinal chemistry. 2019 Mar; 11(6):499-510..
21- Basra MA, Batool M, Farhat F, Tajammal A, Khan H. Anti-inflammatory, anti-thrombotic and Molecular Docking Studies of 1, 3, 4 Oxadiazole Derivatives In Rats. J Biomedical Sci. 2019; 8(2):4.
22- Rayam P, Polkam N, Kuntala N, Banothu V, Anantaraju HS, Perumal Y, Balasubramanian S, Anireddy JS. Design and synthesis of oxaprozin‐1, 3, 4‐oxadiazole hybrids as potential anticancer and antibacterial agents. Journal of Heterocyclic Chemistry. 2020 Mar; 57(3):1071-82.

23- Chama Sh and Sanchit S. Biologically Active Oxadiazo. Asian J.Res.Pharm.Sci. 2015; 5(4): 227-233
24- Thakkar SS, Thakor P, Doshi H, Ray A. 1, 2, 4-Triazole and 1, 3, 4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities. Bioorganic & medicinal chemistry. 2017 Aug 1;25(15):4064-75.
25- Wang PY, Zhou L, Zhou J, Wu ZB, Xue W, Song BA, Yang S. Synthesis and antibacterial activity of pyridinium-tailored 2, 5-substituted-1, 3, 4-oxadiazole thioether/sulfoxide/sulfone derivatives. Bioorganic & medicinal chemistry letters. 2016 Feb 15;26(4):1214-7.
26- Ghasemi B, Najimi M. Antibacterial effect of thiazole derivatives on Rhodoccocus equi, Brucella abortus, and Pasteurella multocida. Iranian Journal of Veterinary Medicine. 2016 Jan 1;10(1):47-52.